Novartis Korea partners with Yuhan Yanghaeng to distribute LabsiDo for chronic urticaria

Novartis Korea announced that its chronic spontaneous urticaria treatment LabsiDo (active ingredient remibrutinib) will be launched in the domestic market using the distribution network and sales capabilities of Yuhan Yanghaeng. The two companies have established a strategic cooperation framework that separates responsibilities for distribution and promotional activities, aiming to improve treatment accessibility for Korean patients and healthcare professionals. On the 3rd, Novartis Korea (CEO Yu Byung-jae) and Yuhan Yanghaeng (CEO Jo Wook-je) signed the partnership agreement and held an event to share their collaboration plans. Under the agreement, Yuhan Yanghaeng will manage the domestic distribution of LabsiDo, while both parties will coordinate promotional efforts to support market entry.